Assessment of Therapeutic Drug Monitoring of Vancomycin in Elderly Patients According to New Guidelines
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Concerns regarding increasing microbial resistance to vancomycin have re- sulted in recommendations for a higher trough serum vancomycin concentration. This study aimed to assess the dosage guidelines targeting vancomycin trough concentrations of 15-20 mg/L. Methods: About 216 adult patients (age, >60 yr) were treated with intravenous vancomy- cin. The patients were divided into 2 groups according to their target vancomycin trough concentrations: the previous guideline group (n=108) treated with targeted vancomycin trough concentrations of 5-15 mg/L from Jan 2009 through April 2011 and the new guide- line group (n=108) treated with targeted concentrations of 15-20 mg/L from November 2011 through July 2012. Results: The 2 groups were not significantly different with respect to age, weight, initial se- rum creatinine, initial creatinine clearance, predictive trough levels, doses, serum drug concentrations, and area under the curve/minimal inhibitory concentrations. Regarding the proportions of vancomycin trough concentrations, the target range was achieved in 50% in the previous guideline group and in 16% in the new guideline group. In the previous and new guideline groups, the trough concentrations of 10-20 mg/dL were observed in 32.4% and 52.8% patients, respectively, and those of <10 mg/L were observed in 45.4% and 29.6%, respectively. Conclusions: Compared to the previous guideline group, the new guideline group showed higher proportions in the therapeutic range of 10-20 mg/L and lower proportions in trough concentrations <10 mg/L. The strictly managed vancomycin therapeutic drug monitoring in the new guideline group was assessed as more effective.
Abstract
Background: Concerns regarding increasing microbial resistance to vancomycin have re- sulted in recommendations for a higher trough serum vancomycin concentration. This study aimed to assess the dosage guidelines targeting vancomycin trough concentrations of 15-20 mg/L. Methods: About 216 adult patients (age, >60 yr) were treated with intravenous vancomy- cin. The patients were divided into 2 groups according to their target vancomycin trough concentrations: the previous guideline group (n=108) treated with targeted vancomycin trough concentrations of 5-15 mg/L from Jan 2009 through April 2011 and the new guide- line group (n=108) treated with targeted concentrations of 15-20 mg/L from November 2011 through July 2012. Results: The 2 groups were not significantly different with respect to age, weight, initial se- rum creatinine, initial creatinine clearance, predictive trough levels, doses, serum drug concentrations, and area under the curve/minimal inhibitory concentrations. Regarding the proportions of vancomycin trough concentrations, the target range was achieved in 50% in the previous guideline group and in 16% in the new guideline group. In the previous and new guideline groups, the trough concentrations of 10-20 mg/dL were observed in 32.4% and 52.8% patients, respectively, and those of <10 mg/L were observed in 45.4% and 29.6%, respectively. Conclusions: Compared to the previous guideline group, the new guideline group showed higher proportions in the therapeutic range of 10-20 mg/L and lower proportions in trough concentrations <10 mg/L. The strictly managed vancomycin therapeutic drug monitoring in the new guideline group was assessed as more effective.
참고문헌 (19)
- 송영구, "한국인에서 Vancomycin의 치료적 약물농도 평가", Infection and Chemotherapy, 36(5), pp.311~318 (2004), 대한감염학회
- MacGowan AP, "Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides", Ther Drug Monit, 20, pp.473~477 (1998)
- 김대일, "Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients", Korean Journal of Pediatrics, 53(12), pp.1000~1005 (2010), 대한소아과학회
- Moellering RC Jr, "Vancomycin: a 50-yr reassessment", Clin Infect Dis, 42(1), pp.3~4 (2006)
- Kollef MH, "Limitations of vancomycin in the management of resistant staphylococcal infections", Clin Infect Dis, 45(3), pp.191~195 (2007)
- Patanwala AE, "Vancomycin dosing for pneumonia in critically ill trauma patients", J Trauma, 67, pp.802~804 (2009)
- Moise-Broder PA, "Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections", Clin Pharmacokinet, 43, pp.925~942 (2004)
- Tobin CM, "Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire", J Antimicrob Chemother, 50, pp.713~718 (2002)
- Rybak M, "Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists", Am J Health Syst Pharm, 66, pp.82~98 (2009)
- Eiland LS, "Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients", Ann Pharmacother, 45, pp.582~589 (2011)
- Verhave JC, "Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index", Am J Kidney Dis, 46, pp.233~241 (2005)
- Patanwala AE, "Vancomycin dosing for pneumonia in critically ill trauma patients", J Trauma, 67, pp.802~804 (2009)
- Cunha BA, "Vancomycin revisited: a reappraisal of clinical use", Crit Care Clin, 24, pp.393~420 (2008)
- Joint Formulary Committee, "British National Formulary" (2008), British Medical Association and Royal Pharmaceutical Society of Great Britain
- del Mar Fernández, "Pharmacokinetic", pharmacodynamic analysis of vancomycin in ICU patients, 2007, pp.33, 279~285
- Pea F, "High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures", J Anti microb Chemother, 45, pp.329~335 (2000)
- American Thoracic Society; Infectious Diseases Society of America, "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia", Am J Respir Crit Care Med, 171, pp.388~416 (2005)
- Sakoulas G, "Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia", J Antimicrob Chemother, 57, pp.699~704 (2006)
- Howden BP, "Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility", Clin Infect Dis, 38, pp.521~528 (2004)